Tabelecleucel
As of the edition of 20 October 2026, Tabelecleucel is a cell: marketed, first approved in 2022 (EU).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Cell
- Brand name
- Ebvallo
- First approved
- 16 December 2022 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Pierre Fabre
- Registered trials
- 6, 1 stopped early
- Disease areas
- Cancer; Infections; Blood and lymph; Immune system; Bones, joints and muscles; Ear, nose and throat
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 1 | 1 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pierre Fabre | Applicant and Lead sponsor of trials | 2017 to now |